Document is current
Any future updates will be listed below
-
Authors
Polimanti, Renato
Walters, Raymond K. https://orcid.org/0000-0001-8422-6530
Johnson, Emma C.
McClintick, Jeanette N. https://orcid.org/0000-0002-6548-4902
Adkins, Amy E. https://orcid.org/0000-0002-3576-3759
Adkins, Daniel E.
Bacanu, Silviu-Alin https://orcid.org/0000-0002-4364-1583
Bierut, Laura J.
Bigdeli, Tim B.
Brown, Sandra https://orcid.org/0000-0001-8780-0323
Bucholz, Kathleen K.
Copeland, William E.
Costello, E. Jane
Degenhardt, Louisa
Farrer, Lindsay A
Foroud, Tatiana M.
Fox, Louis
Goate, Alison M. https://orcid.org/0000-0002-0576-2472
Grucza, Richard
Hack, Laura M.
Hancock, Dana B. https://orcid.org/0000-0003-2240-3604
Hartz, Sarah M. https://orcid.org/0000-0002-5429-3799
Heath, Andrew C.
Hewitt, John K.
Hopfer, Christian J.
Johnson, Eric O.
Kendler, Kenneth S.
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Krauter, Kenneth
Lai, Dongbing https://orcid.org/0000-0001-7803-580X
Madden, Pamela A. F.
Martin, Nicholas G. https://orcid.org/0000-0003-4069-8020
Maes, Hermine H.
Nelson, Elliot C. https://orcid.org/0000-0002-3037-3962
Peterson, Roseann E.
Porjesz, Bernice
Riley, Brien P. https://orcid.org/0000-0002-2408-8268
Saccone, Nancy
Stallings, Michael
Wall, Tamara L.
Webb, Bradley T. https://orcid.org/0000-0002-0576-5366
Wetherill, Leah https://orcid.org/0000-0003-2888-9051
,
Edenberg, Howard J. https://orcid.org/0000-0003-0344-9690
Agrawal, Arpana https://orcid.org/0000-0002-0313-793X
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (U01 MH109532)
- License Information
-
More Information
Article History
Received: 10 September 2019
Revised: 15 January 2020
Accepted: 30 January 2020
First Online: 26 February 2020
Compliance with ethical standards
:
: H.R.K. is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which over the last three years was sponsored by Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor Pharmaceuticals, and Amygdala Neurosciences, Inc. H.R.K. and J.G. are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed on 24 January 2018. L.J.B. and A.M.G. are listed as inventors on Issued U.S. Patent 8080,371, “Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. The spouse of N.S. is listed as an inventor on Issued U.S. Patent 8,080,371, “Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. The other authors do not report any conflict of interest.
